Next 10 |
home / stock / ivevf / ivevf articles
Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceu...
Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmace...
Revenues at €17.5 million for the full year of 2023 up 43.4% compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 millio...
LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with emp...
Daix (France), Long Island City (New York, United States), March 13, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmace...
Inventiva has lifted the voluntary pause on screening and randomization in the NATiV3 clinical trial following the approval from the US central I...
Revenues of €17.5 million for the full year of 2023, compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million, short-t...
Daix (France), Long Island City (New York, United States), January 24, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stag...
Inventiva intends to use the proceeds to fund part of its ongoing pivotal NATiV3 Phase III clinical trial evaluating lanifibranor in patients wit...
News, Short Squeeze, Breakout and More Instantly...
Inventiva SA Company Name:
IVEVF Stock Symbol:
OTCMKTS Market:
Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceu...
Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic d...
Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmace...